Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Tariot and colleagues1 reported that among patients with moderate to severe
Alzheimer disease (AD) receiving stable doses of donepezil, memantine resulted
in significantly better outcomes than placebo on measures of cognition, activities
of daily living, global outcome, and behavior and was well-tolerated. However,
the authors did not describe whether the caregivers of these patients noticed
a difference or whether life was made better for them or for the patients.
Finucane TE. Memantine for Patients With Alzheimer Disease. JAMA. 2004;291(14):1695. doi:10.1001/jama.291.14.1695-a